Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2006 Jun;44(6):1998-2006.
doi: 10.1128/JCM.00104-06.

Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the Linear array HPV genotyping test

François Coutlée  1 , Danielle Rouleau, Patrick Petignat, Georges Ghattas, Janet R Kornegay, Peter Schlag, Sean Boyle, Catherine Hankins, Sylvie Vézina, Pierre Coté, John Macleod, Hélène Voyer, Pierre Forest, Sharon Walmsley; Canadian Women's HIV study Group; Eduardo Franco
Affiliations
Comparative Study

Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the Linear array HPV genotyping test

François Coutlée et al. J Clin Microbiol. 2006 Jun.

Abstract

The Roche PGMY primer-based research prototype line blot assay (PGMY-LB) is a convenient tool in epidemiological studies for the detection and typing of human papillomavirus (HPV) DNA. This assay has been optimized and is being commercialized as the Linear Array HPV genotyping test (LA-HPV). We assessed the agreement between LA-HPV and PGMY-LB for detection and typing of 37 HPV genotypes in 528 anogenital samples (236 anal, 146 physician-collected cervical, and 146 self-collected cervicovaginal swabs) obtained from human immunodeficiency virus-seropositive individuals (236 men and 146 women). HPV DNA was detected in 433 (82.0%) and 458 (86.7%) samples with PGMY-LB and LA-HPV (P = 0.047), respectively, for an excellent agreement of 93.8% (kappa = 0.76). Of the 17,094 HPV typing results, 16,562 (1,743 positive and 14,819 negative results) were concordant between tests (agreement = 96.9%; kappa = 0.76). The mean agreement between tests for each type was 96.4% +/- 2.4% (95% confidence interval [CI], 95.6% to 97.2%; range, 86% to 100%), for an excellent mean kappa value of 0.85 +/- 0.10 (95% CI, 0.82 to 0.87). However, detection rates for most HPV types were greater with LA-HPV. The mean number of types per sample detected by LA-HPV (4.2 +/- 3.4; 95% CI, 3.9 to 4.5; median, 3.0) was greater than that for PGMY-LB (3.4 +/- 3.0; 95% CI, 3.1 to 3.6; median, 2.0) (P < 0.001). The number of types detected in excess by LA-HPV in anal samples correlated with the number of types per sample (r = 0.49 +/- 0.06; P = 0.001) but not with patient age (r = 0.03 +/- 0.06; P = 0.57), CD4 cell counts (r = 0.06 +/- 0.06; P = 0.13), or the grade of anal disease (r = -0.11 +/- 0.06; P = 0.07). LA-HPV compared favorably with PGMY-LB but yielded higher detection rates for newer and well-known HPV types.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Agreement between results obtained for 528 anogenital samples with LA-HPV and PGMY-LB. Kappa coefficients are presented, with 95% CI.
FIG.2.
FIG.2.
Detection rates for HPV types by LA-HPV and PGMY-LB. (a) High-risk types; (b) low-risk types; (c) types with unknown risk. Rates of detection were compared, and P values are shown at the bottom of each graph near the axis. Bars represent 95% CI.
FIG.2.
FIG.2.
Detection rates for HPV types by LA-HPV and PGMY-LB. (a) High-risk types; (b) low-risk types; (c) types with unknown risk. Rates of detection were compared, and P values are shown at the bottom of each graph near the axis. Bars represent 95% CI.
FIG. 3.
FIG. 3.
Correlation between numbers of types detected in each sample by PGMY-LB and LA-HPV. The dashed lines represent the 95% CI of the regression line.
FIG. 4.
FIG. 4.
Differences in numbers of types detected per sample by LA-HPV and PGMY-LB. The number of types detected with PGMY-LB was subtracted from the number of types detected with LA-HPV for each sample. The percentage of the total number of samples is shown above each column.
See this image and copyright information in PMC

References

    1. Aho, J., C. Hankins, C. Tremblay, F. Lang, P. Forest, K. Pourreaux, F. Rouah, The Canadian Women's HIV Study Group, and F. Coutlée. 2003. Molecular analysis of human papillomavirus type 52 isolates detected in the genital tract of HIV-seropositive and seronegative women. J. Infect. Dis. 188:1517-1527. - PubMed
    1. Bauer, H. M., Y. Ting, C. E. Greer, J. C. Chambers, C. J. Tashiro, J. Chimera, A. Reingold, and M. M. Manos. 1991. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 265:472-477. - PubMed
    1. Bosch, F. X., A. Lorincz, N. Munoz, C. J. L. M. Meijer, and K. V. Shah. 2002. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 55:244-265. - PMC - PubMed
    1. Castle, P. E., M. Schiffman, P. E. Gravitt, H. Kendall, S. Fishman, H. Dong, A. Hildesheim, R. Herrero, M. C. Bratti, M. E. Sherman, A. Lorincz, J. E. Schussler, and R. D. Burk. 2002. Comparisons of HPV DNA detection by MY09/11 PCR methods. J. Med. Virol. 68:417-423. - PubMed
    1. Coutlée, F., M. de Ladurantaye, C. Tremblay, J. Vincelette, L. Labrecque, and M. Roger. 2000. An important proportion of genital samples submitted for Chlamydia trachomatis detection by PCR contain small amounts of cellular DNA as measured by β-globin gene amplification. J. Clin. Microbiol. 38:2512-2515. - PMC - PubMed

Publication types

MeSH terms